Clinical Trials
21 results for Kidney/Renal Cancer
Star-tor - Registry For The Evaluation Of The Safety, Tolerability And Efficacy Of Temsirolimus (Torisel®), Sunitinib (Sutent®), And Axitnib (Inlyta®) For The Treatment Of Subjects With Advanced Renal Cell Carcinoma (Mrcc), Mantle Cell Lymphoma (Mcl), And
- Condition: Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors
- Intervention: Drug: Temsirolimus, Drug: Temsirolimus, Drug: Sunitinib, Drug: Sunitinib, Drug: Axitinib
- Study ID: NCT00700258
Phase II Clinical Trial of Docetaxel Plus Cisplatin as Adjuvant Chemotherapy and Concurrent Chemoradiotherapy Versus FOLFOX6 as Adjuvant and 5-FU/CF as Chemoradiotherapy in Patients of Locally Advanced Gastric Cancer After Radical Surgery
- Condition: Gastric Cancer
- Intervention: Drug: DC, Drug: concurrent chemoradiotherapy with 5-FU/CF, Radiation: adjuvant radiation
- Study ID: NCT01889303
An Open-label, Phase II, Registry Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Subjects With Somatostatin Receptor Positive Tumours
- Condition: Carcinoma, Neuroendocrine
- Intervention: Other: Lu-DOTA-TATE radiopharmaceutical
- Study ID: NCT01876771
Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer
- Condition: Breast Cancer, Breast Cancer Stage II-III
- Intervention: Drug: Docetaxel- Carboplatin
- Study ID: NCT01560663
A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs)
- Condition: Salivary Gland Cancer
- Intervention: Drug: bicalutamide + triptorelin, Drug: Cisplatin + Doxorubicin, Drug: Carboplatin + Paclitaxel
- Study ID: NCT01969578
Phase Ib Trial Of Pembrolizumab And Nintedanib
- Condition: Patients With Any Advanced Solid Tumors.
- Intervention: Drug: Nintedanib, Drug: Pembrolizumab
- Study ID: NCT02856425
A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancers
- Condition: Neoplasms
- Intervention: Drug: JNJ-63723283
- Study ID: NCT02908906
A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)
- Condition: Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma
- Intervention: Drug: cabozantinib, Drug: nivolumab
- Study ID: NCT03635892
Prospective Non-interventional Study of Cabozantinib in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment
- Condition: Advanced or Metastatic Renal Cell Carcinoma
- Study ID: NCT03647878
A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Condition: RCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Renal Cancer, Renal Cell Carcinoma, Renal Cell Cancer Metastatic, Renal Cell Carcinoma Recurrent, Renal Cell Cancer, Recurrent, Kidney
- Intervention: Drug: PT2977 in combination with cabozantinib tablets
- Study ID: NCT03634540
Preventive Effects of Low-dose Aspirin as Adjuvant Therapy After Radical Nephrectomy on Disease Recurrence/Metastasis and Survival in Patients With Locally Advanced Renal Cell Carcinoma: an Observational Prospective Cohort Study
- Condition: Aspirin as Adjuvant Therapy in Patients With Surgically Treated High Risk Renal Cell Carcinoma
- Intervention: Drug: Low dose of aspirin
- Study ID: NCT03734614
BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer) - A Translational Study on Immunotherapy for Metastatic Renal Cancer
- Condition: Renal Cancer Metastatic
- Intervention: Biological: Immunological and tumour characterization
- Study ID: NCT03628859
Molecular Analysis for Therapy Choice (MATCH)
- Condition: Advanced Malignant Neoplasm, Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Plasma Cell Myeloma, Refractory Malignant Neoplasm, Refractory Plasma Cell Myeloma
- Intervention: Drug: Afatinib, Drug: Akt inhibitor AZD5363, Drug: Binimetinib, Drug: Crizotinib, Other: Cytology Specimen Collection Procedure, Drug: Dabrafenib, Drug: Dasatinib, Drug: Defactinib, Drug: FGFR Inhibitor AZD4547, Other: Laboratory Biomarker Analysis, Biological: Nivolumab, Drug: Osimertinib, Drug: Palbociclib, Biological: Pertuzumab, Drug: PI3K-beta Inhibitor GSK2636771, Drug: Sapanisertib, Drug: Sunitinib Malate, Drug: Taselisib, Drug: Trametinib, Biological: Trastuzumab Emtansine, Drug: Trk Inhibitor LOXO-101, Drug: Vismodegib, Drug: WEE1 Inhibitor AZD1775
- Study ID: NCT02465060
FASTERCC: Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy. A Randomized, Double-blind Trial From the Danish Renal Cancer Group (DARENCA Study-4)
- Condition: Mucositis
- Intervention: Drug: Folic Acid, Drug: Placebo Oral Tablet
- Study ID: NCT03581773
A Phase III Study Testing the Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic Renal Cell Carcinoma Treated With Sunitinib
- Condition: Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
- Intervention: Behavioral: Concomitant coaching
- Study ID: NCT03013946
Talazoparib and Avelumab in Genomically Defined Metastatic Renal Cell Carcinoma
- Condition: Metastatic Renal Cell Carcinoma, Advanced Retinal Disease Carcinoma
- Intervention: Drug: Talazoparib, Drug: Avelumab
- Study ID: NCT04068831
Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study
- Condition: Advanced Renal Cell Carcinoma (All Subtypes), Metastatic Renal Cell Carcinoma (All Subtypes)
- Intervention: Other: Documentation
- Study ID: NCT04147143
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
- Condition: Advanced Renal Cell Carcinoma
- Intervention: Drug: Nivolumab 240 mg, Drug: Ipilimumab 1mg/kg, Drug: Nivolumab 3mg/kg, Drug: Nivolumab 360mg
- Study ID: NCT03117309
Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
- Condition: Metastatic Renal Cell Carcinoma
- Intervention: Drug: Ipilimumab/ Nivolumab, Radiation: SBRT + Ipilimumab/Nivolumab
- Study ID: NCT04090710
REPLICA: Real Patient Life Treatment With Cabozantinib in Patients With Advanced or Metastatic RCC: A Descriptive and Prospective Non-Interventional Study
- Condition: Advanced or Metastatic Renal Cell Carcinoma
- Study ID: NCT04106349
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
- Condition: Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell
- Intervention: Drug: Cabozantinib, Drug: Cabozantinib S-malate, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Radiation: Radium Ra 223 Dichloride
- Study ID: NCT04071223